全部产品

首页 / 常见产品 / 全部产品

CAS:2692624-22-7|Ceramide C6-d7

  • 产品货号:DT2025061413
  • 发布时间:2025-06-05
  • 产品CAS :2692624-22-7
  • 产品规格:mg(更多包装需求请咨询客服)
  • 产品纯度:≥98%
  • 产品货期:现货下单后48小时内发货,定制产品4-8周。
  • 运输条件:顺丰常规运输
询价
产品详情

货号:DT2025061413
CAS:2692624-22-7
规格:mg(更多包装需求请咨询客服)
纯度:≥98%
生产商:试剂家

生物活性:Ceramide C6-d7 is the deuterium labeled Ceramide C6. Ceramide C6, a Ceramide pathway activator, is an exogenous short-chain ceramide which can induce apoptosis of multiple cancer cells[1][2][3].
体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
试剂家 has not independently confirmed the accuracy of these methods. They are for reference only.
Ceramide C6-d7 相关抗体:
ERK1/2 Antibody
E-Cadherin Antibody (YA470)
Fatty Acid Synthase Antibody (YA766)
DYKDDDDK Tag (FLAG) Antibody
GAPDH Antibody
GFP Antibody
p53 Antibody (YA250)
RUNX2 Antibody
Ferritin Heavy Chain Antibody
COX2 Antibody
Ctip2 Antibody
Cyclin D1 Antibody (YA485)
Cytochrome C Antibody
c-Myc Antibody
Cyclin E1 Antibody
AIF Antibody (YA636)
ALIX Antibody
CNPase Antibody
Cortactin Antibody
COX IV Antibody
COX2/Cyclooxygenase 2 Antibody
Cyclin A2 Antibody
Cyclin B1 Antibody (YA486)
DR5 Antibody
Drosha Antibody
E-Cadherin Antibody (YA778)
EEA1 Antibody
EpCAM Antibody (YA772)
Fatty Acid Synthase Antibody
FIP200 Antibody
分子量:404.68
Formula:C24H40D7NO3
CAS 号:2692624-22-7
非标记 CAS:124753-97-5
性状:液体
颜色:Colorless to light yellow
运输条件:Room temperature in continental US; may vary elsewhere.
储存方式:Solution, -20°C, 2 years
纯度 & 产品资料
纯度: ≥99.0%
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Qiu L, et al. C6-ceramide induces salivary adenoid cystic carcinoma cell apoptosis via IP3R-activated UPR and UPR-independent pathways. Biochem Biophys Res Commun. 2020;525(4):997-1003.
 [Content Brief]
[3]. Liu L, et al. C6-ceramide treatment inhibits the proangiogenic activity of multiple myeloma exosomes via the miR-29b/Akt pathway. J Transl Med. 2020;18(1):298. Published 2020 Aug 3.
 [Content Brief]

常见基团 common groups
Online message

在线留言

欢迎您访问“试剂家 | 纳米靶向科研平台”官方网站,请留下您的需求,我们会派专业人员及时与您联系,并为您提供相应的产品方案。

* 咨询产品
* 您的姓名
* 联系电话
留言内容
验证码
Related Products

相关产品